Drug Eruption and Hepatitis Induced by Antituberculosis Therapy: A Case Report
Abstract
Pulmonary tuberculosis remains a global health issue, with one of the challenges being the adverse side effects of anti-tuberculosis drugs that can interfere with the success of therapy. This case reports a 67-year-old man with pulmonary tuberculosis who experienced a rifampicin-induced drug eruption and pyrazinamide-induced hepatitis during first-line antituberculosis combination therapy. After temporarily discontinuing the antituberculosis regimen, the patient was given supportive therapy with corticosteroid and antihistamine for the drug eruption, and stronger neo-minophagen C injections for the hepatitis. After stabilization, the regimen was adjusted to a combination of isoniazid and ethambutol, and streptomycin was added as the third agent; however, due to an allergic reaction, streptomycin was replaced with levofloxacin. The new regimen, isoniazid-ethambutol-levofloxacin, combined with appropriate management of the adverse reactions resulted in favorable clinical outcomes, marked by the disappearance of the itchy red rash on the face and body, improvement in liver function as seen from liver enzymes and bilirubin levels, and a stable general condition. This case report emphasizes the importance of being aware of the adverse side effects of antituberculosis regimens, especially in elderly patients. Regular monitoring of liver function, early detection of drug reactions, and safe and individualized regimen adjustments are important strategies to prevent complications…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.